Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.

Yoshioka, Kota; Manne-Goehler, Jennifer; Maguire, James H; Reich, Michael R

Yoshioka, Kota; Manne-Goehler, Jennifer; Maguire, James H; Reich, Michael R.

Afiliação

Yoshioka K; Doctor of Public Health Program, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Manne-Goehler J; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Maguire JH; Division of Infectious Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Reich MR; Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

PLoS Negl Trop Dis ; 14(6): e0008398, 2020 06.

Article em En | MEDLINE | ID: mdl-32569280

Assuntos

Doença de Chagas/tratamento farmacológico; Nitroimidazóis/provisão & distribuição; Nitroimidazóis/uso terapêutico; Tripanossomicidas/provisão & distribuição; Tripanossomicidas/uso terapêutico; Fatores Etários; Centers for Disease Control and Prevention, U.S.; Custos de Medicamentos; Drogas em Investigação; Humanos; Nitroimidazóis/economia; Tripanossomicidas/economia; Trypanosoma cruzi; Estados Unidos; United States Food and Drug Administration

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tripanossomicidas / Doença de Chagas / Nitroimidazóis Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google